Evidence map›Paper›PMID 42532646›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Tumor and Organ Dose Estimates from

Zachary Ells, Catherine Meyer, Karam Masri, Marc Ryhiner, David Sennung, Koichiro Kimura, David Mirando, Izabela Tworowska, Rouzbeh Esfandiari, Martin S Allen-Auerbach and 8 more

Abstract readClinical Trial, Phase IIRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Zachary EllsDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California; zells@mednet.ucla.edu.
Catherine MeyerDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Karam MasriDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Marc RyhinerDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
David SennungDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Koichiro KimuraDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
David MirandoMIM Software, Beachwood, Ohio.
Izabela TworowskaRadioMedix Inc., Houston, Texas.
Rouzbeh EsfandiariExcel Diagnostics & Nuclear Oncology Center, Houston, Texas.
Martin S Allen-AuerbachDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Michael LassmannDepartment of Nuclear Medicine, Würzburg University Hospital, Würzburg, Germany.
Ken HerrmannUniversity of Essen, Essen, Germany.
Matthias EiberTechnical University of Munich, Munich, Germany; and.
Wolfgang P FendlerUniversity of Essen, Essen, Germany.
Ebrahim DelpassandRadioMedix Inc., Houston, Texas.
Johannes CzerninDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Magnus DahlbomDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
Jeremie CalaisDepartment of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This is a dosimetry analysis of the prospective randomized phase 2 trial RESIST-PC which evaluated the efficacy and safety of 2 injected activity regimens of [

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantRadiation DosageAgedAged, 80 and overHumansMaleMiddle AgedNeoplasm MetastasisProstate-Specific AntigenRadioisotopesRadiometrySingle Photon Emission Computed Tomography Computed TomographyDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Prostate-Specific AntigenPSMA-617Radioisotopes177Lu-PSMAdosimetryprostate cancerradiopharmaceutical therapy

Identifiers

PMID42532646
PMCPMC13635081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.